Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

Legendre, Christophe; Licht, Christoph; Muus, Petra; A. Greenbaum, Larry; Babu, Sunil; L. Bedrosian, Camille; Bingham, Coralie; Cohen, D.J.; Delmas, Yahsou; Douglas, K.; Eitner, Frank; Feldkamp, Thorsten; Fouque, Denis; R. Furman, Richard; Gaber, Osama; Herthelius, Maria; Hourmant, Maryvonne; Karpman, Diana; Lebranchu, Yvon; Mariat, Christophe; Menne, Jan; Moulin, Bruno; Nürnberger, Jens; Ogawa, Masayo; Remuzzi, Giuseppe; Richard, Tristan; Sberro‐Soussan, Rébecca; Severino, Beth; Sheerin, N.; Trivelli, Antonella; Bernd Zimmerhackl, Lothar; Goodship, Tim; Loirat, Chantal

doi:10.1056/nejmoa1208981

Public

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

Published in New England Journal of Medicine • Jun 5, 2013

Authors:

Christophe Legendre

Christoph Licht

Petra Muus

Abstract

BACKGROUND: Atypical hemolytic-uremic syndrome is a genetic, life-threatening, chronic disease of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion may transiently maintain normal levels of hematologic measures but does not treat the underlying systemic disease. METHODS: We...

Subject

Eculizumab

Atypical hemolytic uremic syndrome

Thrombotic microangiopathy

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!